-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3330 Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)

Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, ALL, Biological therapies, CLL, Lymphomas, non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, indolent lymphoma, aggressive lymphoma, Therapies, Lymphoid Malignancies
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Sunil Bhat, MBBS, MD1*, Sharat Damodar, MBBS, MD, DM1, Pooja Mallya1*, Akshatha Nayak, MD DM1*, Ravi Joshi1*, Bharath Ram S, MBBS, DNB1, Sudarshan Chougule1*, Deepak MB, MD, MBBS1*, Gopinadh Jakka2*, Sudeshna Dhar2*, Anne Roshan Joseph2*, Arun Kumar MG2*, Murugan Palanisamy2*, Jeetendra Kumar2*, Melina Soares2*, Pallavi Arasu2*, Sri Ramulu Elluru2*, Mohammed Manzoor Akheel, MPH MBA2* and Anil Kamat, MD2

1Mazumdar Shaw Medical Centre, Narayana Health City, Bengaluru, India
2Immuneel Therapeutics Private Limited, Bengaluru, India

Background: Varnimcabtagene autoleucel (IMN-003A) is an autologous CD19 directed CAR-T cell product with a 4-1BB co-stimulatory domain and a non-FMC63 murine single chain variable fragment (A3B1 binder), manufactured in India, which is being tested in the IMAGINE study (CTRI/2022/03/041162), a phase-2 clinical trial for patients (pts) with relapsed and/or refractory B cell malignancies (RR BCM). A fractionated infusion of 1 x 106 CAR+ cells (IMN-003A)/kg for B-ALL cohort and 5 x 106 CAR+ cells (IMN-003A)/kg for B-NHL cohort was administered over 3 days (D0, D+1, D+2) as 10%, 30% and 60% fractions after Fludarabine-Cyclophosphamide lymphodepletion regimen (LR). Safety and efficacy results are submitted in a separate abstract (#166297); here we present the early IMN-003A pharmacokinetic data and correlation with disease response.

Methods: IMN-003A was manufactured using cGMP compliant closed system (CliniMACS Prodigy®). The manufacturing data were obtained and analyzed, including % CAR transduction in the final product (FP) by flow cytometry (FC). Peripheral blood (PB) samples were obtained after consent at screening and as per patient schedule after infusion. Persistence of IMN-003A was evaluated in PB after infusion by ddPCR. Safety and efficacy data were collected for analysis. Bone marrow (BM) samples for MRD were obtained at screening, D+28 and D+90 for efficacy. Minimal residual disease (MRD) was performed by FC with 10-4 sensitivity. Apheresis, FP, and PB samples were analyzed for T-cell subpopulations and surface markers by FC.

Results: Eight apheresis were obtained and transduced to achieve the final product with a median manufacturing time of 11d (range 10-18) with 100% success. The mean % transduction of IMN-003A on autologous T cells was 34.77% (range 15.49 - 58.35) with median transgene copies / genome of 2.25 (range 1.49 - 3.83). The mean CD4/CD8 ratio at apheresis and final product was 0.74 and 0.84 respectively. The T-cell subpopulations at apheresis and FP were analyzed (Figure 1A). The mean proportion of CD4 and CD8 positive naïve cells (CCR7+ RA+) was above 90% in the final product (Figure 1A). Median Product doubling time and Apheresis to Infusion time was 1.04d (range 1.02 - 1.38) and 20d (range 16 - 30) respectively. Post IMN-003A infusion, there was reversal of CD4/CD8 ratio in peripheral blood (Figure 1A).

IMN-003A CAR-T cells showed maximum PB expansion (Tmax) at median 10d (range 10 – 14) with median Cmax 180,680 CAR copies / µg gDNA (range 94,675 – 276,412). Among pts with 28-day follow-up, 80% had evidence of CAR+ T cells in PB, with median persistence not reached (range 28 - NR). B-cell aplasia was observed in all pts concurring with CART expansion (Figure 1B). Median loss of B cell aplasia was not reached (range 42 - NR), with no apparent association with response at D+28 and D+90. Hypogammaglobulinemia was noted in 6 of 7 evaluable pts and 2 pts received IVIg. Of evaluable patients with CD4+ T-cell counts below 200/μL, recovery (>200/μL) was seen at median of 10 days (range 2 - 10) after the IMN-003A cell infusion.

None of these pts have relapsed. Of 5 MRD-evaluable pts, response at day +28 (n=4) and +90 (n=1) was 100%. Updated results will be presented at the meeting.

Conclusion: In this industry-led first-in-India phase-2 study, IMN-003A production in a cGMP closed system was feasible and rapid. The peak of CAR-T expansion occurs at median 10d of infusion. The interim responses obtained are deep.

Disclosures: Jakka: Immuneel Therapeutics Private Limited: Current Employment. Dhar: Immuneel Therapeutics Private Limited: Current Employment. Joseph: Immuneel Therapeutics Private Limited: Current Employment. Kumar MG: Immuneel Therapeutics Private Limited: Current Employment. Palanisamy: Immuneel Therapeutics Private Limited: Current Employment. Kumar: Immuneel Therapeutics Private Limited: Current Employment. Soares: Immuneel Therapeutics Private Limited: Current Employment. Arasu: Immuneel Therapeutics Private Limited: Current Employment. Elluru: Immuneel Therapeutics Private Limited: Current Employment. Akheel: Immuneel Therapeutics Private Limited: Current Employment. Kamat: Immuneel Therapeutics Private Limited: Current Employment, Current holder of stock options in a privately-held company.

*signifies non-member of ASH